AstraZeneca spells out a major drop in the risk of death for stage 3 NSCLC patients taking Imfinzi — and why that's important
AstraZeneca’s top team under Pascal Soriot $AZN has spent the past 5 years proving that it could do serious blockbuster development work. And few trials have been as important to forging that rep as PACIFIC, which offered clear evidence that its PD-L1 checkpoint Imfinzi allowed patients with unresectable stage 3 non-small cell lung cancer to live longer.
This morning, AstraZeneca execs turned up at the World Conference on Lung Cancer in Toronto to spell out the promising overall survival data the pharma giant had claimed with a top-line report last spring. The study was published in the New England Journal of Medicine.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.